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Introduction
As sildenafil citrate (Viagra, Pfizer,
New York, NY, USA) was approved
to treat erectile dysfunction (ED), it
has become one of the most popular
drugs worldwide. It improves erectile
function in men with ED by selectively
inhibiting cyclic guanosine monophos-
phate (cGMP)-specific phosphodiester-
ase type 5 (PDE-5), which is present in
all vascular tissues and enhances the
smooth muscle relaxant effects of
nitric oxide (Ballard et al. 1998; More-
land et al. 1998; CDER 1998).
As early as 2000, a letter to the
NEJM (Sponsel et al. 2000) proposed
that sildenafil may benefit patients
with age-related macular degeneration
(AMD), but this idea was not devel-
oped. Choroidal perfusion has since
been reported to be decreased in
AMD (Boltz et al. 2010). Other condi-
tions such as pulmonary hypertension
and cardiac ischaemia have been
found to be favourably treated with
sildenafil (Vlachopoulos et al. 2009).
This current study of changes in cho-
roidal perfusion was instituted to
demonstrate a means of measuring the
effects of sildenafil for possible use in
treating conditions related to choroi-
dal ischaemia, such as AMD.
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ABSTRACT.
Purpose: To demonstrate anatomic and physiologic changes in the human cho-
roid following systemic sildenafil citrate (Viagra) using enhanced depth
imaging spectral domain–optical coherence tomography (EDI-OCT) and
swept-scan high-frequency digital ultrasound.
Methods: Seven healthy male subjects (mean age 32.7 years) were evaluated
at baseline and 2 hr after ingesting 50 mg of sildenafil. Swept-scan high-fre-
quency digital ultrasound and EDI-OCT were utilized to measure choroidal
perfusion and thickness, respectively. Results were read by masked observers.
The Wilcoxon signed-rank test and t-test were used to analyse differences in
choroidal flow and thickness at baseline and 2 hr after ingestion of sildenafil.
Results: Two hours following sildenafil, increased choroidal perfusion was
observed in 11 of 12 eyes measured by swept-scan high-frequency digital ultra-
sound. The mean increase was 3.46 (±2.00) times baseline with a range of
0.47–7.80 times baseline (p = 0.004). Increased choroidal thickness was
observed in 12 of 12 eyes measured with EDI-OCT. The average choroidal
thickness increased by 11.6% temporal to the fovea, 9.3% nasal to the fovea
and 10.7% underneath the fovea (p < 0.001 for all values).
Conclusions: Choroidal perfusion and thickness both increase in response to
systemic sildenafil. These changes could secondarily affect retinal function,
explain previously reported clinical symptoms and potentially be a useful
adjunct for treatment of ocular diseases that would benefit from increased cho-
roidal blood flow.
Key words: age-related macular degeneration – blood flow ⁄ drug effects – choroid ⁄ blood supply
– enhanced depth imaging ocular coherence tomography – sildenafil – swept-scan ultrasound –
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The choroid, which supports the
metabolic function of the outer retina,
has been described as an erectile tis-
sue, analogous in many respects to the
corpus cavernosum (Duke-Elder &
Wybar 1961). The fenestrated choroi-
dal vasculature is highly responsive to
both local and neurogenic stimuli, and
the uveal system may hold up to 97%
of the intraocular blood volume (Paris
et al. 2001). An increase in choroidal
blood flow could secondarily affect
retinal and retinal pigment epithelial
function and could predispose users to
serous retinal detachment or retinal
oedema. Conversely, there is potential
for sildenafil, or similar pharmaco-
logic agents, to be useful adjuncts for
treatment of ocular diseases, which
would benefit from increased blood
flow in the eye. A reliable method of
measuring blood flow in the choroid
may shed light on these issues.
Several studies have looked at the
effect of sildenafil on ocular blood
flow. Sildenafil appears to increase
blood flow velocity significantly in the
retrobulbar circulation, and most
studies suggest an increase in choroi-
dal blood flow with a lesser effect on
the retinal vasculature (Harris et al.
2008). However, reported effects of
sildenafil on ocular circulation have
been inconsistent. Measurements of
choroidal thickness using conventional
ultrasonography found a small incon-
sistent change after sildenafil (McCul-
ley et al. 2002). Vance et al. (2011)
recently demonstrated an increase in
choroidal thickness after sildenafil,
but choroidal perfusion was not mea-
sured. This may reflect the difficulty
in measuring relatively small changes
in the choroidal vasculature by most
available methods. We present a sys-
tem that has allowed us to accurately
make both perfusion and thickness
measurements of the choroid by using
sophisticated ultrasonic and optical
coherence tomography techniques.
Methods
This study was performed under a pro-
tocol approved by the Institutional
Review Board of Weill Medical Col-
lege of Cornell University and adhered
to the tenets of the Declaration of Hel-
sinki. Informed consent was obtained
in writing from all subjects.
Seven male subjects (mean age
32.7 years, range 30–38 years) were
evaluated using swept-scan high-fre-
quency digital ultrasound and
enhanced depth imaging spectral
domain–optical coherence tomogra-
phy (EDI-OCT). Ultrasound was per-
formed on both eyes of five subjects
and only the right eye of two subjects.
Enhanced depth imaging spectral
domain–optical coherence tomogra-
phy was performed on both eyes of
six subjects. One subject underwent
ultrasound but not EDI-OCT. Mea-
surements were obtained at baseline
and 2 hr after 50 mg of systemic silde-
nafil citrate (Pfizer). Subjects were
instructed to refrain from eating for
at least 4 hr prior to the study.
The swept-mode ultrasound tech-
nique we employed is a modification
of the standard B-mode acquisition
process that allows time–domain (as
opposed to Doppler) assessment of
flow by speckle tracking, as previously
described (Kruse et al. 1998; Silver-
man et al. 1999). Speckle tracking is
advantageous in maintaining high spa-
tial resolution in comparison to col-
our-flow Doppler.
Scans were performed using a pro-
totype ultrasound instrument of our
own design. The system utilized a
focused single-element 20 MHz trans-
ducer providing 75 · 225 lm axial-by-
lateral resolution with an imaging
depth of over 3 mm, thus, providing
superior detail of retinal and choroi-
dal structures compared with conven-
tional 10-MHz systems.
Examinations were performed using
an immersion technique with the sub-
ject in a supine position. After estab-
lishing topical anaesthesia with two
drops of proparacaine HCl, a Barra-
quer speculum was inserted to hold
the lids open. With a steridrape sup-
ported by a ringstand forming a
watertight seal about the eye, warm
normal saline solution was used to
establish a fluid standoff medium
between the transducer and the eye.
Range was adjusted to place the
transducer focal zone on the retina,
and the transducer was moved in an
arc such that the focus approximately
followed the retinal curvature. Each
scan consisted of 1024 vectors (lines-
of-sight) spaced at 5-lm increments at
a rate of 500 vectors ⁄ second. Echo
data were digitized at 250 MHz (8-bit
resolution).
In swept-scan mode, successive vec-
tors are placed at intervals much smal-
ler than a beam width. Such vectors
are not independent spatially and are
effectively looking in one direction
over time. This allows particle motion
(i.e. flowing blood cells) to be visual-
ized by detecting local axial shifts in
echo data along successive vectors, as
they are effectively looking at one spa-
tial region over time. A conventional
B-scan image is formed from more
widely spaced, independent vectors.
Because of the relatively slow pulse
repletion frequency of the system
(500 Hz), aliasing (i.e. particles mov-
ing too fast to be tracked by successive
vectors) prevented accurate measure-
ment of particle velocity, but did allow
visualization of perfused tissue
regions. We therefore measured the
fractional area of the choroid with
detectable perfusion rather than parti-
cle velocity or volumetric flow. As
each scan plane consisted of 1024 vec-
tors, data were acquired over a period
of two seconds. Thus, while flow infor-
mation along each vector is instanta-
neous, and thus dependent upon the
relationship to the phase of the cardiac
cycle (to the extent that this affects
choroidal flow), the overall informa-
tion effectively averages out this effect
because of the long duration of data
acquisition. To quantify perfusion, a
masked observer quantified the num-
ber of pixels demonstrating detectable
choroidal perfusion for each scan,
averaging the results of six scans from
each eye. The ratio of post- versus
presildenafil perfused choroidal area
was determined. A one-sample t-test
was performed, testing the hypothesis
that their ratio was unity. Also, a non-
parametric Wilcoxon signed-rank test
was performed. In each case, statistics
were computed for the aggregate
twelve eyes, and separately for the
seven right and five left eyes.
Enhanced depth imaging spectral
domain–optical coherence tomogra-
phy imaging was performed using a
method described previously (Spaide
et al. 2008). Briefly, the choroid was
imaged by positioning the Heidelberg
Spectralis (Heidelberg Engineering,
Heidelberg, Germany) to obtain an
inverted image of the posterior pole.
A 30-degree horizontal section was
obtained, comprising 100 averaged
scans, going directly through the
foveal centre and encompassing the
macula and optic nerve. The Heidel-




GmbH (Carlsbad, CA, USA)] was
used to measure choroidal thickness
from the outer border of the retinal
pigment epithelium to the inner scleral
border by a masked observer. Thick-
ness measurements were obtained
directly at the fovea and at 500-lm
intervals from the fovea out to 3 mm
in the nasal and temporal directions.
The paired t-test was used to analyse
differences in choroidal thickness at
baseline and two hours after ingestion
of sildenafil.
Results
Following systemic sildenafil citrate,
11 of 12 eyes demonstrated increased
choroidal perfusion measured by
swept-scan ultrasound. This was
statistically significant on the Wilco-
xon signed-rank test (Z = )2.18,
p = 0.034) when considering all
twelve eyes. Six of seven right eyes
showed increased perfusion, but this
was not sufficient to reach statistical
significance. All five left eyes showed
increased perfusion, and this was sta-
tistically significant (Z = )2.02,
p = 0.043). The ratio of post-treat-
ment ⁄baseline choroidal perfusion val-
ues ranged from 0.47 to 7.80 and
averaged 3.46 (±2.00). This was sta-
tistically significant by the one-sample
t-test (t = 3.66, p = 0.004, Figs 1
and 2). In the seven right eyes, the
average post-treatment ⁄baseline cho-
roidal perfusion ratio was 3.00
(±2.50), but this was only of border-
line significance (t = 2.12, p =
0.078). In the five left eyes, the aver-
age post-treatment ⁄baseline choroidal
perfusion ratio was 3.50 (±1.57),
which was statistically significant
(t = 3.56, p = 0.024).
Choroidal thickness measured with
EDI-OCT was increased for 12 of 12
eyes (Figs 3 and 4). In right eyes, the
average baseline choroidal thickness
was 291 lm temporal to the fovea,
226 lm nasal to the fovea and 294 lm
underneath the fovea. The average
choroidal thickness in right eyes
increased by 11.7% to 325 lm tempo-
ral to the fovea (Avg = 34.0 lm,
SD = 16.9 lm), 7.5% to 243 lm
nasal to the fovea (Avg = 17.0 lm,
SD = 14.7 lm) and 11.2% to 327 lm
underneath the fovea (Avg =
32.8 lm, SD = 8.3 lm; p < 0.001
for all values). In left eyes, the average
baseline choroidal thickness was
308 lm temporal to the fovea, 239 lm
nasal to the fovea and 316 lm under-
neath the fovea. The average choroi-
dal thickness in left eyes increased by
11.5% to 343 lm temporal to the
fovea (Avg = 35.4 lm, SD = 18.3
lm), 11.0% to 265 lm nasal to the
fovea (Avg = 26.3 lm, SD = 18.8
lm) and 10.2% to 348 lm underneath
the fovea (Avg = 32.2 lm, SD
= 19.5 lm; p < 0.001 for all values).
For all eyes combined, the average
baseline choroidal thickness was
299 lm temporal to the fovea, 232 lm
nasal to the fovea and 305 lm under-
neath the fovea. The average choroi-
dal thickness for all eyes increased by
11.6% to 334 lm temporal to the
fovea (Avg = 34.7 lm, SD = 14.6
lm), 9.3% to 254 lm nasal to the
fovea (Avg = 21.6 lm, SD = 16.1
lm) and 10.7% to 337 lm underneath
the fovea (Avg = 32.5 lm, SD
= 11.2 lm; p < 0.001 for all values).
No serious side effects were noted.
Three of the seven subjects noted a
mild headache and one subject noted
facial flushing, all of which resolved
spontaneously.
Discussion
The limited ability to measure choroi-
dal perfusion and thickness variations
in the living state has prevented satis-
factory documentation of its function,
while it is blood-filled and physiologi-
cally active. We present a system that
has allowed us to make accurate mea-
surements of the choroid by using
sophisticated ultrasonic and optical
coherence techniques. We demonstrate
increased choroidal perfusion and
thickness after ingestion of systemic
sildenafil citrate. There was a statisti-
cally significant increase in choroidal
perfusion as measured by 20-MHz
swept-scan ultrasound, as well as a
statistically significant increase in cho-
roidal thickness as measured by EDI-
OCT 2 hr after 50 mg of sildenafil.
All eyes in our study demonstrated
a significant increase in choroidal
thickness and all eyes, but one, dem-
onstrated an increase in choroidal per-
fusion after sildenafil. This one subject
had what appeared to be a clearly
spurious presildenafil baseline choroi-
dal perfusion measurement. However,
the spurious measurement may have
an anatomical basis. Delay (personal
communication) described an anatom-
ical shunt vessel in the area of our
measurement, and we may have
recorded one of these high-flow ves-
sels. This subject did not have any
observable abnormalities on binocular
ophthalmoscopy.
A previous study (Paris et al. 2001)
used pulsatile ocular blood flow
(POBF) to demonstrate an increase in
non-retinal blood flow (+29.4%,
p = 0.016) 2 hr after 50 mg of sildena-
fil. However, POBF is an indirect mea-



























Fig. 1. Choroidal flow at baseline and 2 hr after 50 mg of sildenafil citrate measured by swept-
scan high-frequency digital ultrasound. The average perfusion ratio was 3.21 times baseline per-
fusion. The perfusion ratio ranged from 0.47 to 7.80 times baseline perfusion (p = 0.004).
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measures general ocular hemodynamics,
of which the choroid comprises a por-
tion. Laser Doppler flowmetry (LDF)
was used to measure choroidal flow in
the foveal avascular zone 1 and 5 hr
after 100 mg of sildenafil (Grunwald
et al. 2001). They did not detect any
change in flow underneath the fovea.
However, LDF is limited in scope and
may not take into account regional dif-
ferences in choroidal flow. Colour
Doppler imaging (CDI) showed an
increase in flow in the ophthalmic
artery, but failed to show an increase in
flow in the central retinal artery or tem-
poral short posterior ciliary artery
(SPCA), which feed the subfoveal cho-
roid, after 50 mg of sildenafil (Du¨ndar
et al. 2001). Of note, it is technically
difficult to locate and assess the SPCA
using CDI. The Retinal Vessel Analy-
ser (RVA, Carl Zeiss Meditech, Dub-
lin, CA, USA) showed an increase in
retinal arterial and venous diameters
after 50 mg of sildenafil, suggesting an
increase in retinal blood flow (Pache
et al. 2002). These results were in con-
flict with those of the previously noted
study by Paris et al. (2001). Histologi-
cal sections from rats fed with sildena-
fil for 4 weeks found an increase in
mean choroidal capillary diameter
(3.44 ± 1.68-lm versus the control of
1.78 ± 1.36-lm, p < 0.001) (Vatansev-
er et al. 2003). A review by Harris et al.
(2008) summarizes these and other
studies looking at the effect of sildenafil
on ocular blood flow using a variety of
techniques, which have shown inconsis-
tent results because of the technical dif-
ficulty of directly measuring choroidal
flow. The method used in the current
study offers significant advantages over
current semi-quantitative methods,
including laser and colour Doppler
technology, by providing truly quanti-
tative localized measurements of perfu-
sion in the choroid.
The vascular coat of the eye has
long been considered responsible for
numerous effects on ocular physio-
logic processes. At least three physio-
logic functions of the choroid have
been described: nutrition, pressure
regulation and dissipation of radiant
energy. A study of blood flow in
albino rabbits revealed a steady and
highly linear flow velocity, suggesting
the importance of the choroid in
supplying physiologic support for the
retina, as well as the ominous retinal



























































Fig. 3. Average choroidal thickness at baseline and 2 hr after 50 mg of sildenafil citrate mea-
sured by enhanced depth imaging optical coherence tomography. The average choroidal thick-
ness for all eyes increased by 11.6% to 334 lm temporal to the fovea, 9.3% to 254 lm nasal to
the fovea and 10.7% to 337 lm directly underneath the fovea (p < 0.001).
(A) (B)
(C) (D)
Fig. 2. Example of a subject demonstrating increased choroidal flow after 50 mg of sildenafil
citrate measured by swept-mode ultrasound. (A) Baseline swept-mode image, indicating retina
(R) and choroid (C). (B) Pretreatment swept-mode image with regions of choroidal perfusion
indicated in red. (C) Swept-mode image 2 hr after sildenafil citrate. (D) Post-treatment swept-
mode image with regions of choroidal perfusion indicated in red. For this eye, the mean perfu-
sion ratio (post ⁄ pre) was 3.01. Images are 3.1 mm in depth.
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man & Oak 1965). The importance of
the choroid was perhaps only mildly
overestimated by Magitot (Wudka &
Leopold 1956), who believed that
‘more than half of ocular pathology is
a consequence of disturbances that
develop in the layers of the choroid.’
The increase in perfusion after silde-
nafil, as demonstrated in our study,
could be clinically relevant in a number
of ocular diseases, including non-arteri-
tic anterior ischaemic optic neuropathy
(NAION), glaucoma, central serous
chorioretinopathy (CSCR), degenera-
tive myopia and AMD. NAION is
thought to be because of decreased per-
fusion within the paraoptic posterior
ciliary arteries that supply the optic
nerve head, but the specific mechanism
remains unproven (Arnold 2001). Hay-
reh (1996) described a ‘watershed zone’
of the posterior ciliary arteries between
the choroid and optic nerve. A change
in ocular haemodynamics may create
an optic nerve ‘steal syndrome’ with
blood flow preferentially channelled to
the choroid instead of the optic nerve
and may be a possible cause of the
reported association of NAION with
sildenafil. Glaucoma patients with peri-
papillary atrophy of choroidal vessels
are at increased risk for glaucoma pro-
gression (Teng et al. 2010). Decreased
choroidal blood flow could plausibly
be involved. Cases of CSCR have been
reported in patients using PDE-5 inhib-
itors (Allibhai et al. 2004; Quiram et al.
2005; Fraunfelder & Fraunfelder
2008). Central serous chorioretinopa-
thy is characterized by a serous eleva-
tion of the neurosensory retina, and it
is plausible that an increase in choroi-
dal flow may incite or exacerbate this
condition. Patients with degenerative
myopia were found to have increased
choroidal thinning related to the degree
of myopia (Fujiwara et al. 2009). An
associated decrease in flow may con-
tribute to retinal atrophy.
The choroid also plays an important
role in the pathogenesis of AMD, in
addition to the retinal pigment epithe-
lium (RPE) and Bruch’s membrane
(Zarbin 2004). Several investigators
have reported significant vascular alter-
ations of the choroid in both ageing
and AMD, such as changes in chorio-
capillaris density and volume, as well
as choroidal vessel diameter (Ramrat-
tan et al. 1994; Spraul et al. 1996). A
non-specific PDE inhibitor, moxaver-
ine, delivered intravenously increased
choroidal flow in patients with AMD
(Pemp et al. 2010). In contrast, sildena-
fil failed to increase choroidal flow in
patients with AMD (Metelitsina et al.
2005). However, measurements in that
study were made using laser Doppler
flowmetry and only in the centre of the
foveola. In another study using ultraso-
nography (Koksal et al. 2005), central
retinal artery velocities were not chan-
ged, but ophthalmic artery and SPCA
velocities were significantly increased
after sildenafil, supporting our findings
of increased choroidal perfusion after
sildenafil.
Hayreh first described ‘watershed
zones’ in the choroid using fluorescein
angiography (Hayreh 1974). In the
case of generalized chronic vascular
insufficiency or diffuse microvascular
insult, these zones could be vulnerable
to ischaemia, especially in the highly
metabolically active macula, where
numerous watershed zones of the
SPCA are found (Hayreh 1990). Age-
related macular degeneration-associ-
ated choriocapillaris dysfunction could
exacerbate these potentially ischaemic
watershed zones resulting in ischaemia
predisposing to choroidal neovascular-
ization or geographic atrophy (Ross
et al. 1998). Ischaemia of the choroid
has been implicated in several studies
of AMD. Increasing choroidal flow in
decreased flow states may be a thera-
peutic target for agents that increase
choroidal blood flow.
In other work in our laboratory, we
demonstrated high-resolution choroi-
dal imaging with a technique called
wavelet analysis, which provides capa-
bility for boundary analysis of the
choroidal and retinal interface to
examine disease-dependent variations
in the microvasculature (Coleman
et al. 2005a; Coleman et al. 2005b).
This provides additional information
for examining the natural history and
for monitoring treatment of choroidal
pathology, such as in AMD. Perfusion
studies using swept-scan and wavelet
ultrasound techniques may be the
ideal way of gauging dosage and tim-
ing of sildenafil and similar agents in
studying choroidal ischaemia in
AMD.
Our study is limited by the small
sample size and in that all our patients
were healthy young men. In addition,
our study was not designed to assess
the complete time course of the effect
of sildenafil on choroidal blood flow.
In summary, we have found
increased choroidal perfusion and
thickness after use of systemic sildenafil
citrate. There was a statistically signifi-
cant increase in choroidal perfusion as
measured by swept-scan ultrasound, as
well as a statistically significant
increase in choroidal thickness as mea-
sured by EDI-OCT after 50 mg of sil-
denafil. These changes could
secondarily affect retinal function and
explain previously reported clinical
symptoms and may also be a poten-
tially useful adjunct for treatment of
ocular diseases that would benefit from
increased choroidal blood flow.
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Fig. 4. Example of a subject demonstrating increased choroidal flow after 50 mg of sildenafil
citrate measured by enhanced depth imaging optical coherence tomography. The choroidal
thickness increased by an average of 40 lm or 16% from baseline in the right eye and 63 lm
or 23% in the left eye.
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